Updates in HR-MDS and AML
Playback speed
10 seconds
IDH Inhibitors in MDS: Frequency & Prognosis, Mutations, Therapy Outcomes, Enasidenib/Ivosidenib, HMA Combinations, Options for Clonal Escape
By
3rd Annual Hematologic Malignancies Symposium
FEATURING
Andrew Wei
By
3rd Annual Hematologic Malignancies Symposium
FEATURING
Andrew Wei
415 views
April 7, 2021
Comments 0
Login to view comments.
Click here to Login